Many Small / Macro Molecule-based STING Pathway Modulators Are Currently Being Evaluated As Monotherapies As Well As In Combination With Other Drugs, Claims Roots Analysis


Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs, claims Roots Analysis

In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).


To order this 310+ page report, which features 170+ figures and 200+ tables, please visit this link


The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments:

  • Types of Payment
  • Upfront Payments
  • Milestone Payments


  • Type of STING Modulator
  • Agonist
  • Antagonist


  • Key Therapeutic Area(s)
  • Oncological Disorders
  • Inflammatory Disorders
  • Infectious Diseases
  • Others


  • Route of Administration
  • Intratumoral
  • Intravenous
  • Oral
  • Subcutaneous
  • Others


  • Type of Molecule
  • Non-nucleotide
  • Cyclic Dinucleotide
  • Live Biotherapeutics
  • Oncolytic Peptides
  • Synthetic Peptides
  • Others


  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific 


The STING Pathway targeting Therapeutics and Technologies, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Aduro Biotech
  • Bristol Myers Squibb
  • Eisai
  • GlaxoSmithKline
  • ImmuneSensor Therapeutics
  • Merck
  • Noxopharm
  • Spring Bank Pharmaceuticals
  • Synlogic


Table of Contents


  1. Preface

    2. Executive Summary

  2. Introduction

  3. STING Pathway Targeting Therapeutics: Current Market Landscape

  4. STING Pathway Targeting Technologies: Current Market landscape

  5. Company Profiles

  6. Academic Grant Analysis

  7. STING Related Initiatives of Big Pharmaceutical Players

  8. Start-up Health Indexing

  9. Publication Analysis

  10. Partnerships and Collaborations


  1. Funding and Investment Analysis

  2. Market Sizing and Opportunity Analysis

  3. Executive Insights


  1. Concluding Remarks


  1. Appendix 1: Tabulated Data


  1. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415


Keywords: pharma,health & care,pharmaceutical,active pharmaceutical ingredient,pharmaceutical product development inc


Other related blogs

Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages

By : Roots Analysis

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer ther..

The antibody drug conjugates market is projected to grow at an annualized rate of over 20%, till 2030

By : Roots Analysis

  Roots Analysis has done a detailed report on Antibody Drug Conjugates Market, covering vario..

The antibody drug conjugates market is estimated to be worth more than 15 billion in 2030

By : Roots Analysis

  Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatme..

The AR / VR based digital marketing service providers in healthcare sector

By : Roots Analysis

Roots Analysis has done a detailed study on “AR / VR based Healthcare Digital Marketing Servic..